Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia. It also develops Switch-DARPin platform, a multispecific cKIT x CD16a x CD47 Switch-DARPin program for targeted and conditional immune cell activation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has license and research collaboration agreements with Novartis Pharma AG to develop DARPin-conjugated radioligand therapies; and collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland. more
Time Frame | MOLN | Sector | S&P500 |
---|---|---|---|
1-Week Return | -3.81% | -2.06% | -0.55% |
1-Month Return | -9.09% | -1.92% | 2.72% |
3-Month Return | 9.5% | -10.4% | 7.66% |
6-Month Return | -33.42% | -4.6% | 10.15% |
1-Year Return | 21.87% | 4.06% | 27.53% |
3-Year Return | -73.16% | 1.94% | 32.31% |
5-Year Return | -73.03% | 36.48% | 89.2% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 20.38M | 9.34M | 9.33M | 189.56M | 7.04M | [{"date":"2019-12-31","value":10.75,"profit":true},{"date":"2020-12-31","value":4.93,"profit":true},{"date":"2021-12-31","value":4.92,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":3.71,"profit":true}] |
Cost of Revenue | 43.50M | 56.08M | 55.72M | 50.75M | 47.84M | [{"date":"2019-12-31","value":77.57,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":99.36,"profit":true},{"date":"2022-12-31","value":90.5,"profit":true},{"date":"2023-12-31","value":85.32,"profit":true}] |
Gross Profit | (23.11M) | (46.73M) | (46.39M) | 138.81M | (40.81M) | [{"date":"2019-12-31","value":-16.65,"profit":false},{"date":"2020-12-31","value":-33.67,"profit":false},{"date":"2021-12-31","value":-33.42,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-29.4,"profit":false}] |
Gross Margin | (113.40%) | (500.12%) | (497.19%) | 73.23% | (579.80%) | [{"date":"2019-12-31","value":-154.86,"profit":false},{"date":"2020-12-31","value":-682.96,"profit":false},{"date":"2021-12-31","value":-678.97,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-791.77,"profit":false}] |
Operating Expenses | 57.04M | 67.67M | 72.75M | 72.94M | 20.30M | [{"date":"2019-12-31","value":78.2,"profit":true},{"date":"2020-12-31","value":92.77,"profit":true},{"date":"2021-12-31","value":99.73,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":27.83,"profit":true}] |
Operating Income | (36.66M) | (58.33M) | (63.42M) | 116.61M | (61.11M) | [{"date":"2019-12-31","value":-31.44,"profit":false},{"date":"2020-12-31","value":-50.02,"profit":false},{"date":"2021-12-31","value":-54.38,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-52.4,"profit":false}] |
Total Non-Operating Income/Expense | 1.89M | (4.38M) | (822.00K) | 1.76M | 2.86M | [{"date":"2019-12-31","value":65.92,"profit":true},{"date":"2020-12-31","value":-153.11,"profit":false},{"date":"2021-12-31","value":-28.7,"profit":false},{"date":"2022-12-31","value":61.56,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Pre-Tax Income | (36.27M) | (62.77M) | (63.78M) | 117.85M | (61.98M) | [{"date":"2019-12-31","value":-30.78,"profit":false},{"date":"2020-12-31","value":-53.27,"profit":false},{"date":"2021-12-31","value":-54.12,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-52.59,"profit":false}] |
Income Taxes | 17.00K | (11.00K) | 2.00K | (1.24M) | 2.25M | [{"date":"2019-12-31","value":0.75,"profit":true},{"date":"2020-12-31","value":-0.49,"profit":false},{"date":"2021-12-31","value":0.09,"profit":true},{"date":"2022-12-31","value":-55.06,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] |
Income After Taxes | (36.29M) | (62.76M) | (63.78M) | 119.09M | (64.24M) | [{"date":"2019-12-31","value":-30.47,"profit":false},{"date":"2020-12-31","value":-52.7,"profit":false},{"date":"2021-12-31","value":-53.56,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-53.94,"profit":false}] |
Income From Continuous Operations | (36.29M) | (62.76M) | (63.78M) | 117.85M | (59.63M) | [{"date":"2019-12-31","value":-30.79,"profit":false},{"date":"2020-12-31","value":-53.26,"profit":false},{"date":"2021-12-31","value":-54.12,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-50.6,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (36.29M) | (62.76M) | (63.78M) | 117.85M | (61.98M) | [{"date":"2019-12-31","value":-30.79,"profit":false},{"date":"2020-12-31","value":-53.26,"profit":false},{"date":"2021-12-31","value":-54.12,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-52.59,"profit":false}] |
EPS (Diluted) | (2.06) | (2.56) | (2.40) | 8.25 | (2.03) | [{"date":"2019-12-31","value":-24.99,"profit":false},{"date":"2020-12-31","value":-31.11,"profit":false},{"date":"2021-12-31","value":-29.13,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-24.58,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
MOLN | |
---|---|
Cash Ratio | 13.76 |
Current Ratio | 14.33 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
MOLN | |
---|---|
ROA (LTM) | -21.17% |
ROE (LTM) | -37.37% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
MOLN | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.10 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.90 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
MOLN | |
---|---|
Trailing PE | NM |
Forward PE | 1.78 |
P/S (TTM) | 32.24 |
P/B | 1.25 |
Price/FCF | NM |
EV/R | 4.94 |
EV/Ebitda | 1.23 |
Molecular Partners AG ADR (MOLN) share price today is $5.3
Yes, Indians can buy shares of Molecular Partners AG ADR (MOLN) on Vested. To buy Molecular Partners AG ADR from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in MOLN stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Molecular Partners AG ADR (MOLN) via the Vested app. You can start investing in Molecular Partners AG ADR (MOLN) with a minimum investment of $1.
You can invest in shares of Molecular Partners AG ADR (MOLN) via Vested in three simple steps:
The 52-week high price of Molecular Partners AG ADR (MOLN) is $12.7. The 52-week low price of Molecular Partners AG ADR (MOLN) is $3.32.
The price-to-earnings (P/E) ratio of Molecular Partners AG ADR (MOLN) is
The price-to-book (P/B) ratio of Molecular Partners AG ADR (MOLN) is 1.25
The dividend yield of Molecular Partners AG ADR (MOLN) is 0.00%
The market capitalization of Molecular Partners AG ADR (MOLN) is $193.53M
The stock symbol (or ticker) of Molecular Partners AG ADR is MOLN